A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice Non-Interventional Phase 4 Study First published 19/04/2020 Last updated 16/04/2024 EU PAS number:EUPAS34763 Study Ongoing